Hu, Xin
Estecio, Marcos R.
Chen, Runzhe
Reuben, Alexandre http://orcid.org/0000-0003-4510-0382
Wang, Linghua http://orcid.org/0000-0001-9380-0266
Fujimoto, Junya
Carrot-Zhang, Jian http://orcid.org/0000-0002-0103-9965
McGranahan, Nicholas
Ying, Lisha
Fukuoka, Junya
Chow, Chi-Wan
Pham, Hoa H. N. http://orcid.org/0000-0002-0998-4486
Godoy, Myrna C. B.
Carter, Brett W.
Behrens, Carmen
Zhang, Jianhua http://orcid.org/0000-0001-5412-9860
Antonoff, Mara B. http://orcid.org/0000-0001-6247-9537
Sepesi, Boris
Lu, Yue
Pass, Harvey I.
Kadara, Humam
Scheet, Paul
Vaporciyan, Ara A.
Heymach, John V. http://orcid.org/0000-0001-9068-8942
Wistuba, Ignacio I.
Lee, J. Jack http://orcid.org/0000-0001-5469-9214
Futreal, P. Andrew http://orcid.org/0000-0001-8663-2671
Su, Dan http://orcid.org/0000-0002-8423-1994
Issa, Jean-Pierre J. http://orcid.org/0000-0003-2258-5030
Zhang, Jianjun http://orcid.org/0000-0001-7872-3477
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (R01CA234629-01)
Article History
Received: 14 July 2020
Accepted: 17 December 2020
First Online: 29 January 2021
Competing interests
: Jianjun Zhang reports research funding from Merck, Johnson & Johnson, and consultant fees from BMS, Johnson & Johnson, AstraZeneca, Geneplus, OrigMed, Innovent outside the submitted work. J.V.H. reports research funding from AstraZeneca, GlaxoSmithKline, and Spectrum; consultant fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, EMD Serono, Foundation Medicine, Hengrui Therapeutics, Genentech, GSK, Guardant Health, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics, Spectrum, and Takeda; licensing fees from Spectrum. I.I.W. reports Honoraria from Genentech/Roche, Bayer, Bristol-Myers Squibb, Astra Zeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Guardant Health, Oncocyte, Flame, and MSD; Research support from Genentech, Oncoplex, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, lovance, 4D, Novartis, and Akoya. H.K. reports funding from Johnson & Johnson and from Janssen Pharmaceuticals. B.S. reports consultant fees from BMS. The other authors declare neither financial nor non-financial interests in the submitted work.